Stuttgart
02.10.26 | 21:56
0,788 Euro
0,00 % 0,000
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mo | Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE (tiratricol) for Patients with MCT8 Deficiency | 160 | GlobeNewswire (Europe) | First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis... ► Artikel lesen | |
| Mo | Egetis Therapeutics AB: Egetis Therapeutics Announces U.S. FDA Approval of EMCITATE (tiratricol) for Patients with MCT8 Deficiency | 163 | GlobeNewswire (Europe) | First and only FDA-approved treatment of peripheral thyrotoxicosis in adults and pediatric patients with monocarboxylate transporter 8 (MCT8) deficiency in the United StatesEgetis launches Egetis RareLink... ► Artikel lesen | |
| 16.09. | Egetis Therapeutics auf Morgan Stanley Konferenz: US-Markteinführung rückt näher | 1 | Investing.com Deutsch | ||
| 11.09. | Egetis Therapeutics auf Cantor-Gesundheitskonferenz: Zulassungsentscheidung für Tiratricol rückt näher | 1 | Investing.com Deutsch | ||
| 31.08. | Egetis Therapeutics AB: Tiratricol Granted Orphan Drug Designation for MCT8 Deficiency in Japan | 221 | GlobeNewswire (Europe) | Stockholm, Sweden, August 31, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm: EGTX), today announced that its partner Fujimoto Pharmaceutical Corporation, which has... ► Artikel lesen | |
| 21.08. | Earnings call transcript: Egetis Therapeutics steigert Umsatz und visiert US-Markteinführung für Emcitate an | 1 | Investing.com Deutsch | ||
| EGETIS THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 21.08. | Egetis Therapeutics AB Q2 Sales Increase | 1 | RTTNews | ||
| 21.08. | Egetis Therapeutics AB: Egetis' Interim report Q2 2026 | 595 | GlobeNewswire (Europe) | FDA's review of Emcitate® NDA progressing according to plan towards September 28, 2026, PDUFA action dateEgetis granted patent for MCT8 Deficiency Composition in the U.S.Emcitate sales in Europe during... ► Artikel lesen | |
| 10.06. | Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency | 464 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 10, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(Nasdaq Stockholm:EGTX), an innovative pharmaceutical company focused on late-stage... ► Artikel lesen | |
| 10.06. | Egetis Therapeutics AB: Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency | 242 | GlobeNewswire (Europe) | Stockholm, Sweden, June 10, 2026. Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm: EGTX), an innovative pharmaceutical company focused on late-stage development and commercialization... ► Artikel lesen | |
| 19.05. | Egetis Therapeutics: Egetis to Present Healthcare Resource Drivers and Cost in MCT8 Deficiency at ISPOR 2026 | 547 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX)(NASDAQ Stockholm:EGTX) today announced its participation in the annual conference... ► Artikel lesen | |
| 07.05. | Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 | 501 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 7, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (Nasdaq Stockholm:EGTX) today announced that the Company is planning to participate in several... ► Artikel lesen | |
| 05.05. | Egetis Therapeutics: Egetis Announces Grant of Patent for MCT8 Deficiency Composition in The U.S. | 478 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 5, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office (USPTO)... ► Artikel lesen | |
| 30.04. | Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026 | 293 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 30, 2026 / Egetis Therapeutics (STO:EGTX) - Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX), today announced its participation... ► Artikel lesen | |
| 29.04. | Egetis Therapeutics AB: Interim report Q1 2026 | 1.111 | GlobeNewswire (Europe) | Egetis Announced FDA Acceptance and Priority Review of NDA for Emcitate® (tiratricol) for MCT8 Deficiency · Egetis completed the U.S. New Drug Application (NDA) for Emcitate® in January· ... ► Artikel lesen | |
| 21.04. | Egetis Therapeutics AB: Egetis Therapeutics has successfully carried out a directed share issue amounting to SEK 350 million (approximately USD 38 million) | 233 | GlobeNewswire (Europe) | NOT FOR PUBLICATION, DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, ISRAEL, JAPAN, NEW ZEALAND, SOUTH AFRICA... ► Artikel lesen | |
| 14.04. | Egetis Therapeutics AB: Bulletin from Egetis Therapeutics' Annual General Meeting 2026 | 377 | GlobeNewswire (Europe) | Stockholm, Sweden, April 14, 2026. Egetis Therapeutics AB (publ) (STO: EGTX) today announced that the Annual General Meeting (AGM) has been held on April 14, 2026, at which the submitted proposals were... ► Artikel lesen | |
| 09.04. | Egetis Therapeutics: Egetis Appoints Tiago Nunes as Chief Medical Officer | 785 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / April 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (STO:EGTX), today announced the appointment of Tiago Nunes, MD, PhD, as Chief Medical Officer... ► Artikel lesen | |
| 27.03. | Egetis Therapeutics: Egetis Announces FDA Acceptance and Priority Review of NDA for Emcitate for MCT8 Deficiency | 841 | ACCESS Newswire | NDA submission for Emcitate successfully validated by the FDAPriority Review granted and PDUFA target action date set to September 28, 2026Emcitate (tiratricol) is eligible to receive a Priority Review... ► Artikel lesen | |
| 09.03. | Egetis Therapeutics: Egetis Receives Notice of Allowance for MCT8 Deficiency Composition Patent in the U.S. | 479 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / March 9, 2026 / Egetis Therapeutics AB (publ) ("Egetis" or the "Company") (NASDAQ Stockholm:EGTX) today announced that the United States Patent and Trademark Office... ► Artikel lesen |
1 2 Weiter >>
30 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| NOVO NORDISK | 33,210 | -0,48 % | Novo Nordisk gerät trotz GLP-1 unter Druck - warum Eli Lilly und Co. schon Milliarden in neue Plattformen investieren | ||
| SANOFI | 71,08 | -0,03 % | Laufende Fusionskontrollverfahren: Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald) | Datum der Anmeldung:24.09.2026Aktenzeichen:B3-102/26Unternehmen:Sanofi, Paris/FR; Erwerb eines Minderheitsanteils an der Cheplapharm SE (Gemeinschaftsunternehmen mit der Braun Invest Holding GmbH, Greifswald)Produktmärkte:Arzneimittel... ► Artikel lesen | |
| GSK | 20,870 | -1,04 % | JEFFERIES stuft GSK auf 'Buy' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für GSK mit einem Kursziel von 2500 Pence auf "Buy" belassen. B7H3-Antikörper seien eine der am meisten unterschätzten Chancen... ► Artikel lesen | |
| ASTRAZENECA | 139,30 | 0,00 % | Summit to Pair with AstraZeneca, Daiichi Sankyo to Evaluate Ivonescimab as Combination Therapy | ||
| TILRAY BRANDS | 3,215 | +0,31 % | Tilray Brands, Inc.: BrewDog Builds Momentum for Next Growth Chapter with Expanded Senior Leadership Team | New appointments strengthen marketing, hospitality, category, and international commercial leadership as BrewDog advances long-term growth under Tilray BrandsELLON, Scotland and LONDON, Sept. 28, 2026... ► Artikel lesen | |
| VERTEX PHARMACEUTICALS | 448,45 | +0,04 % | $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth This Much Today | ||
| DERMAPHARM | 37,500 | -2,47 % | JEFFERIES stuft Dermapharm auf 'Hold' | NEW YORK (dpa-AFX Analyser) - Das Analysehaus Jefferies hat die Einstufung für Dermapharm nach einem Treffen mit dem Finanzchef Christof Dreibholz mit einem Kursziel von 44 Euro auf "Hold" belassen.... ► Artikel lesen | |
| QUANTUM BIOPHARMA | 2,922 | -3,18 % | Rodman & Renshaw Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$8 Price Target | TORONTO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of... ► Artikel lesen | |
| NEKTAR THERAPEUTICS | 38,650 | -0,21 % | Nektar Therapeutics: New Rezpegaldesleukin Data Supporting Long-term Durability and Disease Improvement in Patients with Alopecia Areata and Atopic Dermatitis at EADV Congress 2026 | Rezpegaldesleukindemonstrateddurabilityanddeepeningofresponsethroughone year of treatment in two dermatological indications, reinforcing the differentiated properties... ► Artikel lesen | |
| TONIX PHARMACEUTICALS | 7,968 | +0,84 % | Tonix Pharmaceuticals Holding Corp. - 8-K, Current Report | ||
| FILANA THERAPEUTICS | 0,891 | +8,00 % | XFRA PX91: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| AXSOME THERAPEUTICS | 158,40 | -0,44 % | Axsome Therapeutics, Inc.: Axsome Therapeutics Announces Results of the Shared Goals Survey of Caregivers of Patients with Alzheimer's Disease Agitation Presented at Psych Congress 2026 in Connection with World Alzheimer's Day | The Shared Goals: Navigating Alzheimer's Agitation survey finds that Alzheimer's disease agitation is often only recognized after daily life is significantly disrupted Ninety-seven percent of care... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 10,400 | -0,48 % | SONDERMELDUNG: Könnte die Aktie von SELLAS Life Sciences Group Inc jetzt komplett einbrechen? - Jetzt handeln, noch vor dem Wochenende! | ||
| OPKO HEALTH | 1,330 | -5,00 % | OPKO HEALTH, INC. - 8-K, Current Report | ||
| TG THERAPEUTICS | 48,400 | +0,41 % | TG Therapeutics, Inc.: TG Therapeutics Announces Initiation of Phase 2 Trial Evaluating BRIUMVI in Patients with Treatment-Resistant Schizophrenia | NEW YORK, July 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced the initiation of a Phase 2 clinical trial evaluating BRIUMVI® (ublituximab-xiiy), in adults with treatment-resistant... ► Artikel lesen |
EGETIS THERAPEUTICS AB gehört der Branche Pharma an. Der aktuelle Kurs liegt bei 0,788 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EGETIS THERAPEUTICS AB finden Sie auf Wallstreet Online.